Paul L. Crispen
0000-0002-3699-6183
Publication & Citation Trends
Publications
0 total
Statins Are Not Associated with Improved Bladder Cancer Outcomes in Patients with Early-Stage Bladder Cancer Treated with BCG Immunotherapy
Cited by 0
Semantic Scholar
EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL
Cited by 1
Semantic Scholar
PD48-01 EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL
Cited by 0
Semantic Scholar
Case report: A novel somatic SDHB variant in a patient with bladder paraganglioma OA
Cited by 1
Semantic Scholar
Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial Carcinoma.
Cited by 0
Semantic Scholar
Abstract A169: Overcoming tumor-associated immune suppression and resistance to cancer immunotherapy using Hyal2-ADCC
Cited by 0
Semantic Scholar
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). OA
Cited by 46
Semantic Scholar
Research Topics
Renal cell carcinoma treatment
(80)
Bladder and Urothelial Cancer Treatments
(64)
Renal and related cancers
(51)
Cancer Immunotherapy and Biomarkers
(32)
Immune cells in cancer
(28)
Affiliations
Fox Chase Cancer Center
Mayo Clinic
University of Kentucky
Emory University
University of Michigan–Ann Arbor